What Has Been the Progress and Growth of the Denosumab Market in Recent Years?
The denosumab market has seen considerable growth due to a variety of factors.
• There has been a swift expansion in the denosumab market size over the past few years. It is predicted that it will surge from $3.27 billion in 2024 to $3.7 billion in 2025, registering a compound annual growth rate (CAGR) of 13.1%.
The upward trend during the historic period can be tied to factors such as advancements in clinical trials and research, FDA approvals and regulatory checkpoints, heightened awareness regarding bone health, along with strategic collaborations and marketing drives.
How Does the Forecast Look for the Denosumab Market?
The denosumab market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for denosumab is predicted to expand rapidly. By 2029, it is forecasted to reach a worth of $5.59 billion with a compound annual growth rate (CAGR) of 10.9%.
The expected growth within the forecast period can be tied to the increasing occurrences of bone metastases, progress in cancer treatments, the commonness of osteoporosis, and the augmented understanding of osteoporosis, together with regulatory green lights for new uses. Key trends within this period include strategic cooperation and partnerships, integration into digital health solutions, the growth of new uses and clinical applications, and advancements within biosimilar development.
What Are The Leading Drivers Of Growth In The Denosumab Market?
The growth of the denosumab market is anticipated to be boosted by the rising incidence of osteoporosis. Osteoporosis is a health condition which weakens the bones, leading to decreased bone density and increased fracture risk. Denosumab is employed in osteoporosis treatment by inhibiting bone resorption via the targeted RANK ligand. As indicated by data from the National Center for Biotechnology Information, a US governmental agency, the Canadian Longitudinal Study on Aging in September 2023 showed the prevalence of physician-diagnosed osteoporosis to be 12.7% and DXA-proven osteoporosis at 5.9% for female community-dwelling elderly. Furthermore, a cross-sectional study executed by Buttros et al revealed the incidence of osteoporosis in postmenopausal women aged between 40 and 75 to be 24.6%, diagnosed using bone mineral density (BMD) measurements. This surge in osteoporosis incidence is therefore propelling the denosumab market expansion.
How Are The Segments Defined Within The Global Denosumab Market?
The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
Pre-Book The Denosumab Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Denosumab Market?
Leading players in the denosumab market are striving to maintain their competitive stance by rolling out innovative solutions, including premier treatments for osteoporosis. The term "first-line treatment for osteoporosis" refers to the initial treatment method endorsed by medical practitioners for individuals diagnosed with the bone condition. As an example, in November 2022, China's Boan Biotech secured approval from the country's National Medical Products Administration (NMPA) for its denosumab biosimilar product, Boyoubei, becoming the first company in China to produce a denosumab injection. The company is also preparing it for markets beyond China, including Europe and the United States, with an aim to globally market it. Various treatment guidelines have suggested the drug as a superior treatment for osteoporosis. The drug potentially promises to significantly reduce the risk of hip, non-vertebral, and vertebral fractures among this group of patients. Moreover, Boyoubei is the world's first biosimilar to Prolia (the original creator of denosumab) granted approval for global distribution.
Who Are the Key Players In The Denosumab Market?
Major companies operating in the denosumab market report are:
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Novartis International AG
• Sanofi SA
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Asahi Kasei Corporation
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company
• Limited
• Mylan N.V.
• Sandoz International GmbH
• Daiichi Sankyo Company Limited
• Aurobindo Pharma Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Celltrion Inc.
• Amneal Pharmaceuticals Inc
• Cadila Healthcare Limited
• Lupin Limited
• Biocon Limited
• Torrent Pharmaceuticals Ltd.
• Jubilant Life Sciences Limited
• Ajanta Pharma Limited
What Is The Most Dominant Region In The Denosumab Market?
North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
